RET and cancer: These include neurotrophic tyrosine receptor kinase (NTRK) inhibitors larotrectinib and entrectinib, dorstarlimab-gxly (an anti-PD-1 antibody), pembrolizumab for cancers with high tumor mutational burden (TMB-H), the combination of dabrafenib and trametinib for BRAFV600E gene mutated cancers, and selpercatinib for RET-fused cancers [1].